S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
What is carbon capture and why does it keep coming up at COP28?
All the trading advice you’ve ever received boils down to this (Ad)
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
Dozens of animals taken from Virginia roadside zoo as part of investigation
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
What is carbon capture and why does it keep coming up at COP28?
All the trading advice you’ve ever received boils down to this (Ad)
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
Dozens of animals taken from Virginia roadside zoo as part of investigation
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
What is carbon capture and why does it keep coming up at COP28?
All the trading advice you’ve ever received boils down to this (Ad)
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
Dozens of animals taken from Virginia roadside zoo as part of investigation
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
What is carbon capture and why does it keep coming up at COP28?
All the trading advice you’ve ever received boils down to this (Ad)
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
Dozens of animals taken from Virginia roadside zoo as part of investigation
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes

Akari Therapeutics Stock Price, News & Analysis (NASDAQ:AKTX)

$3.12
-0.03 (-0.95%)
(As of 12/8/2023 ET)
Compare
Today's Range
$3.06
$3.26
50-Day Range
$2.91
$3.88
52-Week Range
$2.81
$11.43
Volume
6,794 shs
Average Volume
8,595 shs
Market Capitalization
$17.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

AKTX stock logo

About Akari Therapeutics Stock (NASDAQ:AKTX)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

AKTX Stock Price History

AKTX Stock News Headlines

Akari Therapeutics (AKTX) Earnings Dates & Reports
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Akari Therapeutics, Plc (CLA.F)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Akari Therapeutics to Present at Emerging Growth Conference
British pharma opens U.S. headquarters in Boston
Akari Therapeutics, Plc Announces ADS Ratio Change
See More Headlines
Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/31/2020
Today
12/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKTX
Employees
15
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.48 per share

Miscellaneous

Free Float
2,159,000
Market Cap
$17.63 million
Optionable
Not Optionable
Beta
1.13
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Ms. Rachelle Suzanne Jacques (Age 52)
    President, CEO & Director
    Comp: $1.38M
  • Ms. Wendy F. DiCicco CPA (Age 56)
    Interim Chief Financial Officer
  • Ms. Melissa Bradford-Klug (Age 53)
    Chief Operating Officer
  • Dr. Miles Nunn (Age 54)
    Chief Scientific Officer
  • Dr. John F. Neylan III (Age 70)
    M.D., Executive VP & Chief Medical Officer
  • Ms. Beth-Anne Lang
    Senior Vice President of Regulatory Affairs
  • Annie Mack
    Financial Controller














AKTX Stock Analysis - Frequently Asked Questions

How have AKTX shares performed in 2023?

Akari Therapeutics' stock was trading at $9.3980 at the beginning of the year. Since then, AKTX shares have decreased by 66.8% and is now trading at $3.12.
View the best growth stocks for 2023 here
.

Are investors shorting Akari Therapeutics?

Akari Therapeutics saw a decrease in short interest in November. As of November 15th, there was short interest totaling 11,200 shares, a decrease of 36.0% from the October 31st total of 17,500 shares. Based on an average daily volume of 15,200 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.2% of the company's shares are short sold.
View Akari Therapeutics' Short Interest
.

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics, Plc (NASDAQ:AKTX) announced its quarterly earnings data on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.80) by $5.00.

When did Akari Therapeutics' stock split?

Akari Therapeutics shares reverse split on the morning of Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Akari Therapeutics own?
Who are Akari Therapeutics' major shareholders?

Akari Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (3.15%).
View institutional ownership trends
.

How do I buy shares of Akari Therapeutics?

Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AKTX) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -